"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension that investigates the effect of the addition of dulaglutide (0.75 and 1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baseline in hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus"

"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension that investigates the effect of the addition of dulaglutide (0.75 and 1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baseline in hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus"

2022-06-30